Cocrystal Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
COCP Nasdaq 2830 www.cocrystalpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cocrystal Pharma, Inc.

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - Apr 24th, 2025 12:00 pm
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - Apr 16th, 2025 12:00 pm
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR - Apr 10th, 2025 4:25 pm
COCP: Norovirus Challenge Study Planned for 2025… - Apr 1st, 2025 2:15 pm
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - Mar 31st, 2025 12:00 pm
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Mar 14th, 2025 12:35 pm
Life Sciences Investor Forum Agenda Announced for March 13th - Mar 12th, 2025 5:12 pm
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 - Mar 6th, 2025 1:00 pm
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Feb 11th, 2025 8:11 pm
COCP: Phase 2a Trial of CC-42344 Extended… - Jan 8th, 2025 1:05 pm
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections - Jan 8th, 2025 1:00 pm
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial - Jan 2nd, 2025 11:34 am
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement - Dec 31st, 2024 7:03 pm
Top Midday Decliners - Dec 31st, 2024 6:21 pm
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - Dec 31st, 2024 1:00 pm
US Penny Stocks To Watch In December 2024 - Dec 17th, 2024 8:07 pm
COCP: Multiple Upcoming Catalysts… - Nov 19th, 2024 2:14 pm
November 2024 US Exchange Standouts: Promising Penny Stocks - Nov 15th, 2024 12:09 am
Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - Nov 13th, 2024 1:00 pm
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins - Oct 31st, 2024 12:00 pm